Reshaping the HIV treatment and prevention landscape
Meningococcal franchise
Aim to double revenues in next decade, building on world-leading MenB vaccine
High growth opportunity through market
expansion
- 1.2m cases of Invasive Meningococcal
Disease (IMD) worldwide annually
-
Severe & devastating; ~10% mortality rate
- Only ~17-25% receive MenB vaccine¹
gsk
Potential best-in-class
portfolio & pipeline
-
-
-
Market leader >50% share in a ~£2bn market with
proven benefit backed by real world evidence²
Sustaining leadership & expanding market with Men
ABCWY. In Phase 3 - 2024* launch
World's broadest coverage for all ages with improved
convenience, 2nd Gen ABCWY in Phase 1-2
-
-
BEXSERO®
Meningococcal Group B Vaccine
1. Teens between 13-17y in US; source: National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2019 | MMWR (cdc.gov)
2. N Engl J Med 2020; 382:309-31; * Subject to regulatory approval
Meningitis ambition uses 2020 base.
MENVEO
65View entire presentation